細胞療法相關的合作與授權協議（2016-2026 年）

細胞治療領域交易的明確指標

細胞治療領域的合作是由高度專業化的治療方法所驅動的，其合約結構反映了複雜的開發過程、生產要求和高附加價值創新。

本報告對超過 1080 項細胞療法合作及許可協議進行了全面系統的分析，清晰且基於證據地展示了整個市場夥伴關係的設計、談判和執行方式。

充分了解市場標準。

本報告將使您準確了解細胞療法交易的實際結構，使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解交易條款如何根據治療方法類型、開發階段和合作夥伴情況而有​​所不同。
• 支持基於證據的評估和合約結構確定。
• 內部討論應基於實際交易數據，而不是假設。
• 了解大型公司如何處理交易
• 在技​​術複雜且快速發展的治療領域，我們將合作夥伴的行為和重複交易模式視覺化。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，從而可以詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解細胞治療夥伴關係中價值、風險和控制權的分配方式至關重要，尤其是在涉及生產規模擴大、供應鏈考量和監管複雜性的領域。
• 專為實際業務發展和策略制定而設計。

本報告廣泛用於以下用途：

• 建立和評估先進醫療技術交易。
• 在清晰的市場環境下準備談判
• 許可、聯合開發和平台合作關係評估
• 支持以可靠證據為基礎的數據驅動型內部策略。
• 本報告內容
• 超過1080項細胞療法合作及授權協議
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 可全文搜尋的合約目錄（依公司、治療方法和開發階段分類）。
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 分析交易趨勢、關鍵交易案例和活躍的交易商。
• 關於細胞治療領域交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易覆蓋範圍和合約層面的見解，為如何在細胞治療領域建立、談判和評估夥伴關係提供了可靠的、基於證據的參考資料。

目錄

執行摘要

第1章：引言

第2章：細胞治療領域的交易趨勢

• 介紹
• 細胞療法已經
• 最活躍的細胞療法交易相關人員
• 與細胞療法相關的交易（按交易類型）
• 與細胞治療相關的交易（按治療領域分類）
• 細胞療法交易（按行業分類）
• 細胞治療交易的條款和條件

第3章：細胞治療領域的主要交易

• 介紹
• 關於高價值細胞療法的寶貴資訊

第4章：細胞療法交易中最活躍的相關人員

• 介紹
• 最活躍的細胞療法交易相關人員
• 最活躍的細胞治療交易夥伴的公司簡介

第5章：細胞治療合約談判指南

• 介紹
• 細胞療法合約交易目錄

第6章 依技術類型分類的細胞療法交易

• 特價優惠列表
• 交易清單 - 細胞療法交易資訊（依公司分類）(AZ)
• 交易清單 - 按交易類型分類的細胞療法交易
• 特價優惠清單 - 按治療領域分類的細胞療法特價優惠
• 交易類型的定義
• 關於這家研究公司
• 當前夥伴關係
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for cell therapy dealmaking

Cell therapy partnering is driven by advanced and highly specialised therapeutic approaches, with deal structures reflecting complex development pathways, manufacturing requirements, and high-value innovation.

This report provides a comprehensive and structured analysis of 1080+ cell therapy collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how cell therapy deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by therapy type, development stage, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a technically complex and rapidly evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within cell therapy partnerships, particularly in areas involving manufacturing scale-up, supply chain considerations, and regulatory complexity.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark advanced therapy transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing, co-development, and platform partnerships
• Support internal strategy with robust, defensible data
• What's included
• 1080+ cell therapy collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy type, and development stage)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for cell therapy dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cell therapy partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

• 2.1. Introduction
• 2.2. Cell therapy deals over the years
• 2.3. Most active cell therapy dealmakers
• 2.4. Cell therapy deals by deal type
• 2.5. Cell therapy deals by therapy area
• 2.6. Cell therapy deals by industry sector
• 2.7. Deal terms for cell therapy deals
  • 2.7.1 Cell therapy deals headline values
  • 2.7.2 Cell therapy deal upfront payments
  • 2.7.3 Cell therapy deal milestone payments
  • 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

• 3.1. Introduction
• 3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

• 4.1. Introduction
• 4.2. Most active cell therapy dealmakers
• 4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

• Deal directory
• Deal directory - Cell therapy deals by company A-Z
• Deal directory - Cell therapy deals by deal type
• Deal directory - Cell therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cell therapy deals since 2016
• Figure 2: Active cell therapy dealmaking activity since 2016
• Figure 3: Cell therapy deals by deal type since 2016
• Figure 4: Cell therapy deals by therapy area since 2016
• Figure 5: Cell therapy deals by industry sector since 2016
• Figure 6: Cell therapy deals with a headline value
• Figure 7: Cell therapy deals with an upfront value
• Figure 8: Cell therapy deals with a milestone value
• Figure 9: Cell therapy deals with a royalty rate value
• Figure 10: Top cell therapy deals by value since 2016
• Figure 11: Most active cell therapy dealmakers since 2016
• Figure 12: Cell therapy deals by technology type since 2016